United States Patent 4,810,643: Claim Scope, Validity Friction Points, and Landscape Position
United States Patent 4,810,643 (the “’643 patent”) is a gene-to-product patent centered on DNA sequences encoding human pluripotent granulocyte colony-stimulating factor (hpG-CSF), with asserted embodiments spanning: (i) purified genomic/cDNA constructs, (ii) manufactured coding sequences with codon-preferred variants for bacterial and yeast expression, (iii) labeled single-stranded probes, (iv) expression vectors, (v) transformed host cells, and (vi) processes for producing the encoded G-CSF polypeptide (including specified point variants such as Ala1 or Ser17 forms).
The claim set is broad at the functional level (host expression in prokaryotic and eukaryotic systems; “part or all” of primary structure and “hematopoietic biological activity”), but it narrows in critical places by tying DNA to specific sequence sets described as FIGS. 2 and 3, by hybridization to those sequences, and by codon-degeneracy equivalents. The patent also locks in multiple specific sequence-to-product points via enumerated amino-acid substitutions and cataloged analogs (claims 12, 16, 20).
1) What do the independent claims actually cover?
Independent claim language across the set is distributed, but claims 1, 2, 11, 13, 15 form the core coverage scaffolding: DNA molecules (claims 1/2/11), vectors (claim 13), cells (claim 14), and processes (claim 15). The remaining claims tend to narrow by specifying DNA type (cDNA/genomic/made DNA), host expression optimization (codon-preferred for E. coli or yeast), labeled probes (claims 8-10), specific host categories (claims 22-24, 25-27), or specific product variants (claims 12, 16, 20, and the corresponding vector/cell/product claims).
Claim coverage map (functional to structural)
| Patent element |
Claim numbers |
Scope style |
Key narrowing feature |
| DNA defined by sequence sets + hybridization + codon degeneracy |
1 |
Sequence/hybridization |
DNA in (a) FIGS. 2 and 3 or complements; (b) hybridizing to (a); (c) codon-degenerate equivalents |
| DNA encoding hpG-CSF (full or partial primary structural conformation; hematopoietic activity) |
2 |
Functional product mapping to sequence |
Requires encoding hpG-CSF activity/conformation |
| cDNA, genomic DNA, manufactured DNA |
3-5 |
Structural DNA class |
DNA type restrictions; still tied to claim 2 subject matter |
| Codon-preferred manufactured DNA |
6-7 |
Expression engineering |
Includes codons preferred for E. coli or yeast |
| Labeled detectable DNA probes (incl. radiolabeled) |
8-10 |
Diagnostic/probe form |
Covalently attached label; single-strand version |
| DNA encoding hpG-CSF fragments/analogs w/ hematopoietic activity |
11 |
Functional analog mapping |
Must code fragment/analog possessing hpG-CSF biological activity |
| Enumerated amino-acid variants |
12, 16, 20 |
Product-anchored |
Examples of Ala1 hpG-CSF, Ser17 hpG-CSF, and a list of Met-1/Ser-x variants |
| Vectors containing covered DNA |
13, 18 |
Vehicle |
“Biologically functional plasmid or viral DNA vector” |
| Transformed host cells |
14, 19, 21-27 |
Vehicle |
Stable transformation/transfection allowing expression |
| Process for making polypeptide by expressing covered DNA |
15, 28-30 |
Method |
Host class variants (E. coli, yeast, mammalian) |
| Polypeptide product |
17 |
Product-by-process style |
“Polypeptide product of expression” (tied to claim 15 DNA) |
Critical point: The patent is not only claiming expression constructs and production processes; it claims DNA itself in multiple forms (including hybridization-anchored sets and manufactured variants). That mix increases both enforceability value (more entry points for infringement) and invalidity friction (prior art typically attacks DNA sequences, and functional broadness increases written-description and enablement pressure).
2) How broad is “hybridize” and “codon degeneracy” in claim 1?
Claim 1 is structured as a classic “sequence capture” claim:
- (a) DNA molecules “set out in FIGS. 2 and 3 or their complementary strands”
- (b) “DNA molecules which hybridize to the DNA molecules defined in (a) or fragments thereof”
- (c) DNA molecules which, but for degeneracy of the genetic code, would hybridize to the DNA molecules defined in (a) and (b)
From an infringement-engineering perspective, claim 1 potentially captures:
- Direct sequence equivalents to FIG. 2/3 transcripts or their complements.
- Variants that retain sufficient complementarity to meet “hybridize” conditions (implicitly requiring the specification to define stringency, although the claim itself does not).
- Silent mutations that preserve amino-acid sequence (codon degeneracy) yet would otherwise hybridize.
From an validity and enforceability perspective, this drafting is high-risk:
- “Hybridization” claims frequently face disputes over what degree of complementarity and what hybridization conditions are required. If the specification does not provide a clear standard, claims can be vulnerable to indefiniteness-style challenges.
- “Codon degeneracy” claims can broaden beyond what was actually disclosed if “equivalents” include numerous alternative codons, especially when the gene is within a genus of possible sequences encoding the same protein.
Practically, for portfolio planning, claim 1 is the most important claim to interpret in light of: (i) whether FIGS. 2 and 3 specify nucleotide sequences with clear boundaries, and (ii) whether the specification defines hybridization conditions with enough precision to distinguish the captured sequences from prior art.
3) Do the functional terms widen claim scope beyond the disclosed sequences?
Both claims 1 and 2 repeatedly invoke functional markers:
- “for use in securing expression in a prokaryotic or eukaryotic host cell”
- polypeptide product having “at least a part of the primary structural conformation and the hematopoietic biological activity of naturally-occurring pluripotent granulocyte colony-stimulating factor”
Claim 11 similarly covers “polypeptide fragment or polypeptide analog” possessing “hematopoietic biological activity.”
This is a double-edged construction:
- Enforcement benefit: It can cover homologs and fragments that retain function even if not identical to the full-length native G-CSF sequence, as long as the DNA fits the claimed DNA definition (claim 11 is DNA coding for fragment/analog, still anchored by the biological activity requirement).
- Invalidity friction: If multiple DNA constructs encoding functionally similar fragments exist in the prior art, these functional terms may not distinguish adequately. Also, “primary structural conformation” is a demanding biological concept; if the patent does not map which parts of the primary structure are required, the claim can be argued as overbroad relative to disclosure.
For business strategy, the key is that the “DNA capture” language in claim 1 (FIGS. 2/3, hybridization, codon degeneracy) likely does more to constrain scope than the functional polypeptide language. Meanwhile, claims 2 and 11 can be argued as functional at the product level, which increases litigation volatility.
4) Where are the claim anchors that lower freedom-to-operate (FTO) risk?
The risk to competitors is most concentrated where claims specify either:
1) the exact sequence set (FIGS. 2 and 3), or
2) specific amino-acid variants (Ala1 hpG-CSF; Ser17 hpG-CSF; and enumerated Met-1/Ser-x combinations), or
3) “manufactured DNA” with defined codon-preference for E. coli or yeast, and
4) vectors/cells that allow expression of those specific constructs.
Enumerated protein variants (hard anchors)
The enumerated claims serve as strong anchors because they tie the claim path to a defined protein variant class:
- Claim 12: DNA coding for [Ala¹] hpG-CSF
- Claim 16: DNA coding for [Ser¹⁷] hpG-CSF
- Claim 20: DNA coding for analogs selected from:
- [Met⁻¹] hpG-CSF
- [Ser³⁶] hpG-CSF
- [Ser⁴²] hpG-CSF
- [Ser⁶⁴] hpG-CSF
- [Ser⁷⁴] hpG-CSF
- [Met⁻¹, Ser¹⁷]
- [Met⁻¹, Ser³⁶]
- [Met⁻¹, Ser⁴²]
- [Met⁻¹, Ser⁶⁴]
- [Met⁻¹, Ser⁷⁴]
These anchors are often the difference between “functional overlap” and “sequence-variant infringement.” If a competitor makes G-CSF variants that do not include these specific substitutions or do not produce the claimed activity profile as mapped by the patent, non-infringement arguments can tighten.
5) How does the patent allocate claim scope to platform (bacterial vs yeast vs mammalian)?
The patent explicitly covers:
- DNA encoding hpG-CSF for “prokaryotic or eukaryotic host expression” (claim 2)
- manufactured coding sequences with codons preferred for E. coli (claim 6)
- manufactured coding sequences with codons preferred for yeast (claim 7)
- vectors containing covered DNA (claims 13, 18)
- transformed cells (claims 14, 19, 21-27)
- processes using E. coli (claim 28), yeast (claim 29), mammalian (claim 30)
That allocation matters because manufacturing routes are often where competitors try to design around:
- If a competitor uses expression systems that do not match the claimed codon-preference or avoids “manufactured DNA” formulations, it may still fall into claims 1/2/11 if its DNA sequences meet the hybridization/codon-degeneracy capture.
- If a competitor avoids the FIG-defined sequences and instead uses different gene designs with synonymous changes that do not hybridize (under the claimed standard), it can potentially navigate around claim 1. That is hard to do without a defined hybridization stringency standard and without a full sequence comparison.
6) Claim-by-claim critical points (what is most litigable)
Claims 1-4: Sequence capture and DNA class
- Claim 1 is the broadest DNA “capture.” Its hybridization-based scope is the litigation magnet.
- Claims 2-4 narrow to DNA encoding hpG-CSF, cDNA, and genomic DNA. If the prior art contains protein-coding sequences for G-CSF, these claims can still be invalid if the DNA sequences are not meaningfully distinct.
Claims 5-7: “Manufactured DNA” and codon preference
- These claims focus on codon optimization for E. coli and yeast.
- In an obviousness framework, codon optimization can be argued as routine unless the patent ties codon preference to specific functional outcomes beyond the standard expression enhancement.
Claims 8-10: Labeled single-stranded DNA
- These are probe/diagnostic-type claims. The competitor design-around is possible by using alternative labeling chemistries or probe forms, but if the probe sequence is captured by claim 1’s hybridization capture, the claim can still reach.
Claims 11-12, 16, 20: Analogs and specific substitutions
- These are narrower and stronger for enforcement. Competitors using the same substitutions face more direct product-variant collision.
- The biggest risk for competitors is that these variants may have been claimed broadly enough in earlier art to challenge novelty or nonobviousness, depending on disclosure history.
Claims 13-14, 18-19, 21-27: Vectors and host cells
- These are vehicle and use claims that typically inherit vulnerabilities from underlying DNA claims. If the DNA claims are invalid or narrow too much, vehicles collapse.
Claims 15, 28-30: Production process
- These claims are process-by-expression. They are often infringed by standard biomanufacturing if the DNA and constructs match the claimed scope.
- Process claims can sometimes survive even if some composition claims fail, but here the process depends on expression using DNA of claims 1/2/11 (claim 15), so DNA validity drives process validity.
7) Patent landscape positioning: where ’643 sits against the G-CSF gene space
Without access to the full prosecution history, file wrapper, and co-citations from the patent itself (including the patent’s cited references), a complete, source-backed mapping of forward/backward citations is not possible here. What can be stated from the claim architecture alone is that ’643 is positioned at the intersection of:
- early gene isolation and nucleic acid claims for therapeutic cytokines,
- expression system optimization (bacterial and yeast codon-preference),
- vector and host claims (a standard enforcement backbone in early biologics patenting), and
- specific amino-acid variant claims (which function as sub-portfolio “islands” within a broader gene family claim).
Critical competitive implication: The patent’s breadth is most dangerous in two situations:
1) competitors using the exact gene sequences (or direct complements) corresponding to FIGS. 2 and 3, and
2) competitors making one of the enumerated Met-1 and Ser-x variants.
The patent’s breadth is least dangerous when competitors:
- use a different underlying gene sequence that does not meet the hybridization capture (again, dependent on hybridization stringency definition), and
- avoid the enumerated protein substitutions.
Key Takeaways
- ’643 is a nucleic acid-first patent that expands enforcement through hybridization and codon-degeneracy capture (claim 1), while anchoring key value in enumerated G-CSF variants (claims 12, 16, 20).
- The most litigable term is the hybridization-based definition in claim 1, which can be disputed around complementarity and hybridization conditions.
- “Manufactured DNA” with codon preference for E. coli and yeast (claims 6-7) targets expression-system implementation, but it can face obviousness pressure as routine gene optimization.
- Vector/cell/process claims (claims 13-15 and 18-30) are structurally tied to the underlying DNA claims, so their enforceability tracks the fate of claim 1/2/11.
FAQs
1) Which claim is the main entry point for DNA infringement risk?
Claim 1, because it captures DNA defined by FIGS. 2 and 3, complements, and hybridization/codon-degeneracy equivalents.
2) Do the enumerated protein variants materially narrow the scope?
Yes. Claims 12, 16, and 20 require specific amino-acid substitutions (Ala¹, Ser¹⁷, and Met⁻¹/Ser-x combinations), creating more defined infringement targets than purely functional analog language.
3) Does the patent cover codon-optimized constructs for bacterial and yeast expression?
Yes. Claims 6 and 7 explicitly cover manufactured DNA including codons preferred for E. coli and for yeast.
4) Are probe claims included?
Yes. Claims 8-10 cover covalently labeled detectable DNA, including radiolabeled single-stranded DNA.
5) Can competitors mitigate risk by switching host organisms?
Switching host organisms alone may not avoid infringement because claims cover multiple host classes (including prokaryotic, eukaryotic, and mammalian) as long as the DNA used falls within the claimed sequence definitions and expression enabling constructs.
References
[1] United States Patent 4,810,643.
